CARE Ratings downgrades Themis Medicare to CARE BB+
Themis Medicare (THEMISMED) said CARE Ratings has downgraded its credit rating to CARE BB+, covering facilities or instruments of about ₹100 crore. The company is valued at about ₹1,063 crore.
What happened
Themis Medicare (THEMISMED) told the exchanges on 9 October 2026 at 11:54 AM that CARE Ratings has downgraded its credit rating to CARE BB+, covering facilities or instruments of about ₹100 crore.
From the filing: "Crore) Rating Remarks Long Term Bank Facilities 77.39 CARE BB+;"
Company snapshot
Themis Medicare is a small-cap company, with a market value of about ₹1,063 crore.
The stock last traded at ₹115.5, against a 52-week range of ₹64.95–₹147 (21.4% below the high).
Before this filing the shares had moved −13.2% over the month and −0.5% over three months. Average daily turnover over the last 20 sessions was about ₹1.31 crore.
Promoters held 67.11% at the end of Q1 FY27; 43.39% of promoter shares were pledged. Foreign institutions owned 0.01% and domestic institutions 0.01%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 98 | -14.2 | -1.54 |
| Q2 FY26 | 78 | -3.6 | -0.39 |
| Q3 FY26 | 90 | 10.1 | 1.1 |
| Q4 FY26 | 77 | 8.9 | 0.96 |
| Q1 FY27 | 87 | 24.6 | 2.67 |
What history shows
This is not the company's first credit rating disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Market-wide, 1,252 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Any change in borrowing costs, covenants or further rating actions.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.